详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China [2]Department of Drug Discovery and Development, Argorna Pharmaceuticals Co., Ltd, Guangzhou, China [3]Department of Manufacturing, Guangzhou RiboBio Co., Ltd, Guangzhou, China [4]Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China [5]Guangdong Provincial Key Laboratory of Drug Non-clinical Evaluation and Research, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangzhou, China [6]State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, Macau SAR, China

出处：

DOI：

关键词： SARS-CoV-2 bivalent mRNA vaccine variants of concern (VOCs) immunogenicity broad-spectrum efficacy

摘要：

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has rapidly spread around the globe. With a substantial number of mutations in its Spike protein, the SARS-CoV-2 Omicron variant is prone to immune evasion and led to the reduced efficacy of approved vaccines. Thus, emerging variants have brought new challenges to the prevention of COVID-19 and updated vaccines are urgently needed to provide better protection against the Omicron variant or other highly mutated variants.Here, we developed a novel bivalent mRNA vaccine, RBMRNA-405, comprising a 1:1 mix of mRNAs encoding both Delta-derived and Omicron-derived Spike proteins. We evaluated the immunogenicity of RBMRNA-405 in BALB/c mice and compared the antibody response and prophylactic efficacy induced by monovalent Delta or Omicron-specific vaccine with the bivalent RBMRNA-405 vaccine in the SARSCoV-2 variant challenge.Results showed that the RBMRNA-405 vaccine could generate broader neutralizing antibody responses against both Wuhan-Hu-1 and other SARS-CoV-2 variants, including Delta, Omicron, Alpha, Beta, and Gamma. RBMRNA-405 efficiently blocked infectious viral replication and lung injury in both Omicron- and Delta-challenged K18-ACE2 mice.Our data suggest that RBMRNA-405 is a promising bivalent SARS-CoV-2 vaccine with broad-spectrum efficacy for further clinical development.Copyright © 2023 Ma, Li, Ma, Zhang, Zhang, Zhong, Wen, Wang, Yan, Xiong, Wu, Guo, Yang, Yang and Zhang.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 2 区免疫学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区免疫学

第一作者：

第一作者机构： [1]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

共同第一作者：

通讯作者：

通讯机构： [1]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China [2]Department of Drug Discovery and Development, Argorna Pharmaceuticals Co., Ltd, Guangzhou, China [4]Laboratory of Computational Biomedicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China [6]State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, Macau SAR, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Broad-spectrum antiviral activity of Spatholobus suberectus Dunn against SARS-CoV-2, SARS-CoV-1, H5N1, and other enveloped viruses [2]Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays. [3]Risk factors for the critical illness in SARS-CoV-2 infection: a multicenter retrospective cohort study. [4]Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines. [5]Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2. [6]Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CLpro inhibitors [7]The influence of pre-existing hypertension on coronavirus disease 2019 patients [8]Potent Antibody Response Elicited by a Third Booster Dose of Inactivated COVID-19 Vaccine in Healthy Subjects [9]Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China [10]Effectiveness of Booster Doses of the SARS-CoV-2 Inactivated Vaccine KCONVAC against the Mutant Strains